Develop a rapid point of care diagnostic test for liver disease.
2021 - Ongoing
We have successfully developed a first-generation ALT test and are now developing improved reagents scalable for manufacture. We will include alternate and additional liver disease biomarkers for evaluation and possible inclusion in future versions of the lateral flow or ELISA assays.
Liver disease is routinely diagnosed by measuring ALT levels in the blood. Elevated ALT levels can be due to chronic viral hepatitis (B or C), alcohol consumption, drug toxicity or fatty liver disease. Pathology labs in high income countries can provide results within hours, but this is not the case in resource constrained settings, including remote and rural Australia and low income countries. In these settings, a rapid point of care diagnostic test could form the basis of a liver health check tool, promoting awareness and management of liver disease.
- DJPR VMRAF
- The Collie Foundation
- St Vincent’s Hospital
- Austin Hospital
Meet the project team. Together, we are translating research into better health, for all.